Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Trump Says Anthropic No Longer Seen as National Security Threat 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
LA JOLLA, Calif., Feb. 04, 2016 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at 2:15 p.m. ET (11:15 a.m. PT) on Thursday, February 11, 2016 at the 5th Annual Leerink Global Healthcare Conference in New York. The conference will be held at The Waldorf Astoria Hotel in New York City.
A live audio webcast and replay will be available in the Investors section of Kura Oncology's corporate website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura's pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor that is currently in three Phase 2 clinical studies: the first study in patients with locally advanced solid tumors that carry HRAS mutations; the second study in patients with peripheral T-cell lymphomas; and the third study, an investigator-sponsored Phase 2 trial, in patients with urothelial carcinoma tumors characterized by HRAS mutations. Kura’s preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL inhibitor program. For additional information about Kura Oncology, please visit www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849 5375 [email protected]
